Growing evidence suggests that protein phosphatases play a major role in antagonizing the aberrant phosphorylation caused by oncogenic kinase signalling in cancer cells (Bononi et al, 2011) . Protein phosphatase 2A (PP2A) is a major intracellular serine/threonine (Ser/Thr) phosphatase, which acts as a heterotrimeric holoenzyme complex composed of the structural A and catalytic C subunits, and with various regulatory B subunits. The scaffold A subunit coordinates the assembly of the catalytic C subunit with a wide variety of regulatory B subunits that contribute to substrate specificity and correct subcellular compartmentalization of the PP2A holoenzyme (Xu et al, 2006; Saraf et al, 2010; Perrotti & Neviani, 2013) . Given the diversity of PP2A subunit composition, PP2A forms complexes with many different substrates and accounts for a significant portion of Ser/Thr phosphatase activity in eukaryotic cells. Physiologically, PP2A controls the cell cycle and possesses pro-apoptotic activity via negative regulation of the PI3K/Akt pathway (Janssens & Rebollo, 2012; Kurimchak & Grana, 2012) . It is well documented that PP2A, as a tumour suppressor, is frequently inactivated in human cancers (Sontag, 2001 ). In myeloid leukaemia, PP2A is functionally inhibited rather than genetically mutated (Ramaswamy et al, 2015) . The non-genetic dysregulation of PP2A results from posttranslational modifications on the catalytic C subunit (Chen et al, 1992; Sents et al, 2013) , and interactions with cellular inhibitor proteins by its scaffold A and regulatory B subunits (Neviani et al, 2005; Junttila et al, 2007) . It has been suggested that pharmacological re-activation of PP2A to combat the inhibitory mechanisms may have anti-leukaemic efficacy (Cristobal et al, 2011; Ramaswamy et al, 2015) .
KIAA1524, also known as cancerous inhibitor of protein phosphatase 2A (CIP2A), is one of the key cellular inhibitors of PP2A (Junttila et al, 2007) . Overexpression of KIAA1524 leads to PP2A inactivation and increases phosphorylation toward several oncogenic substrates, such as MYC (Junttila et al, 2007) and Akt (Chen et al, 2009) . KIAA1524 was found to be aberrantly expressed in various malignancies and associated with poor prognosis (Vaarala et al, 2010; Bockelman et al, 2011 Bockelman et al, , 2012 Wang et al, 2011; Xu et al, 2012) . KIAA1524 has been identified as a key determinant of disease progression in chronic myeloid leukaemia (CML) (Lucas et al, 2011) , and a prognostic factor in normal cytogenetic acute myeloid leukaemia (AML) (Barragan et al, 2015) , suggesting that KIAA1524 could be a therapeutic target in leukaemia. However, the impact of KIAA1524 targeting and the associated molecular events in leukaemia remain to be determined.
Prior studies have shown that treatment with the proteasome inhibitor, bortezomib, suppresses KIAA1524 expression, leading to PP2A activation, Akt dephosphorylation/inactivation and, consequently, cellular apoptosis in solid tumour cells (Lin et al, 2012; Tseng et al, 2012) . Carfilzomib is a second-generation proteasome inhibitor with reduced adverse effects and can be used effectively in place of bortezomib (Berenson et al, 2014) . Recently, a phase III head-to-head study revealed the superiority of carfilzomib over bortezomib in patients with relapsed multiple myeloma (NCT01568866). Given the effect of bortezomib on the KIAA1524/PP2A pathway, the present study examined whether carfilzomib exhibits anti-leukaemic activity through KIAA1524 inhibition and PP2A activation.
In this report, we showed that targeting KIAA1524 with carfilzomib induced leukaemia cell apoptosis. Interestingly, the apoptotic effect of carfilzomib was not related to proteasome inhibition, but associated with KIAA1524 downregulation, PP2A activation and, p-Akt dephosphorylation. Mechanistically, the suppression of KIAA1524 by carfilzomib occurred at the transcriptional level via ELK1. Moreover, carfilzomib demonstrated anti-tumour activity in HL-60 xenograft mice. The in vivo anti-tumour effect of carfilzomib mirrored its in vitro effect on KIAA1524/PP2A/p-Akt signalling.
Materials and methods

Reagents
Carfilzomib was purchased from MedKoo Biosciences (Chapel Hill, NC, USA). For in vitro experiments, various concentrations of carfilzomib were dissolved in dimethyl sulfoxide (DMSO) and then added to cells in RPMI-1640 medium (Invitrogen, San Diego, CA, USA) supplemented with 5% fetal bovine serum. The final DMSO concentration was 0Á1% after addition to the medium. Okadaic acid (OA) and 1,9 dideoxy-forskolin were purchased from Cayman Chemical (Ann Arbor, MI, USA). Cycloheximide (CHX) was purchased from Sigma-Aldrich (St Louis, MO, USA).
Proteasome inhibition assays
In vitro measurements of the proteasome inhibition in drug-treated cells were performed by a 20S Proteasome Activity Assay kit (Chemicon International, Temecula, CA, USA). The assay is based on detection of the fluorophore 7-Amino-4-methylcoumarin (AMC) after cleavage from the labelled substrate LLVY-AMC, a known substrate commonly used for measuring chymotrypsin-like peptidase activity of the 20S proteasome. All procedures were conducted according to the manufacturer's instructions. Briefly, cells were treated with or without 200 nmol/l carfilzomib. After treatment for 12 h, cells were lysed and the protein concentrations were quantified. The proteasome activity was determined by measurement of free AMC fluorescence generated from the equal amounts of protein of each sample incubation with the proteasome substrate (fluorophorelabelled substrate) by a fluorometer with a 380/460 nm filter set.
Cell culture and primary leukaemia or haematopoietic cells HL-60, KG-1, THP-1 and K562 cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). All the leukaemia cell lines were cultured in RPMI-1640 medium (Invitrogen) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 lg/mL streptomycin in a humidified incubator and an atmosphere of 5% CO 2 at 37°C in air. Normal CD34 + haematopoietic stem cells were obtained from consenting autologous or allogeneic donors for haematopoietic stem cell transplantation. Primary cells were collected from the bone marrow of patients with newly diagnosed acute leukaemia, CML, or Burkitt lymphoma with marrow involvement. This study was approved by the ethics committee of the Institutional Review Board of Taipei Veterans General Hospital. All informed consents from sample donors were in accordance with the Declaration of Helsinki and were obtained at the time of their donation. Western blot analysis Cells were exposed to the reagents at the indicated concentrations for various periods of time and prepared for immunoblotting. Western blot analysis was performed as previously reported (Tseng et al, 2012) . The primary antibodies of Ets-1 (ETS1), ELK1, ubiquitin and KIAA1524 for immunoblotting were from Santa Cruz Biotechnology (San Diego, CA, USA). Other antibodies, such as anti-caspase-3, anti-JNK, P-JNK (Thr138/Tyr185), Bax, MYC-tag and p-Akt (Ser473), were from Cell Signaling (Danvers, MA, USA).
Apoptosis assay
Drug-induced apoptotic cell death was assessed by Western blot analysis of caspase activation and propidium iodide flow cytometric assay. For assessment of apoptosis (sub-G1) in primary cells, specific cell death was calculated with the formula: (xt-xm/100-xm)/100, where xt was the number of apoptotic cells in response to a given carfilzomib concentration and xm was the apoptotic cells among the untreated cells (Liu et al, 2013) .
Transfection
HL-60 cells were transfected with MYC-tagged KIAA1524 as previously described (Liu et al, 2013) . KIAA1524 (CIP2A) cDNA was purchased from Origene (Catalogue number RC219918; Rockville, MD, USA) and constructed into the pCMV6 vector.
Immunoprecipitation phosphatase assay
PP1 and PP2A phosphatase activity were measured with cell lysates (500 lg) prepared from the whole cell lysates using an Immunoprecipitation Phosphatase Assay Kit (Millipore, Billerica, MA, USA), following the manufacturer's protocol. Briefly, PP2ACa was immunoprecipitated with anti-PP2A, C subunit, clone 1D6 (Catalogue number 05-421; Millipore) monoclonal antibody and the PPP1Ca (protein phosphatase 1, catalytic subunit, alpha isozyme) was immunoprecipitated with anti-PPP1A (Catalogue number GTX105255; GeneTex Inc., San Antonio, TX, USA) polyclonal antibody and protein A-agarose beads. Then the beads were collected by the centrifugation and washed with Ser/Thr assay buffer. Thereafter, phosphopeptide (K-R-pT-I-R-R) was added to the washed beads (at final concentration 250 lmol/l), followed by incubation at 30°C for 15 min. After centrifugation, 25 ll of supernatant was transferred to an assay plate; 100 ll of Malachite Green phosphate detection solution was added and incubated at 30°C for 15 min for colour development. 
Dual-luciferase reporter assay
The promoter activity of KIAA1524 was determined using the dual-luciferase reporter assay kit (Promega) according to the manufacturer's instructions. HL-60 cells were co-transfected with the luciferase reporter constructs pGL4.17-KIAA1524-promoter (Firefly luciferase reporter) and PGL4.74-renilla (Renilla luciferase reporter) as an indicator of normalization of transfection efficiency. At 24-h posttransfection, cells were treated with carfilzomib (50 nmol/l) or DMSO for 24 h, then lysed and assayed for luciferase activity. The promoter activity was repeated three times in parallel for statistical analysis.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was performed using the Pierce Agarose ChIP Kit (Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer's instruction. Briefly, HL-60 cells were treated with carfilzomib 50 nmol/l or DMSO for 24 h. Physical cross-linking between chromatin (DNA) and proteins was fixed by 1% formaldehyde at room temperature for 10 min. Then, cells were lysed for DNA digestion by enzyme (micrococcal nuclease, 37°C, 15 min); phosphatase inhibitor and protease inhibitor were added in the cell lysis step to avoid protein degradation. Lysates were clarified by centrifugation at 12 500 9 g for 5 min at 4°C. Immunoprecipitation was performed by adding ELK1, or rabbit IgG antibodies as the negative control. The immunocomplex was precipitated by incubation with 25 ll of protein A/G magnetic beads for 1 h at 4°C. The protein/DNA complex was eluted using 200 ll of elution buffer from the beads. Cross-linking of protein-DNA was reversed by adding 8 ll of 5 mol/l NaCl at 95°C for 15 min. The DNA was purified using spin columns and 2 ll of the DNA was used in the semi-PCR reaction for amplification of the KIAA1524 promoter region (-139/-16 bp). Anti-RNA polymerase II antibody and GAPDH primers were provided by the manufacturer as a positive control for assay technique and reagent integrity.
Xenograft tumour growth
The animal study was approved by the Institutional Animal Care and Use Committee of Taipei Veterans General Hospital. All experimental procedures using these mice were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of Taipei Veterans General Hospital. Male NCr athymic nude mice (5-7 weeks of age) were purchased from the National Laboratory Animal Centre (Taipei, Taiwan) and maintained in a specific pathogen-free (SPF)-environment. Each mouse was inoculated subcutaneously in the dorsal flank with 5 9 10 6 leukaemia cells suspended in 100 ll of a 1:1 mixture of phosphate-buffered saline and Matrigel (BD Biosciences, Bedford, MA, USA) under isoflurane anesthesia. Tumours were measured using callipers and their volumes calculated using a standard formula (width 2 9 length 9 0Á52). When tumours reached 200-300 mm 3 , mice were administered an intraperitoneal injection of carfilzomib (0Á5 mg/kg body weight) twice weekly for 2 weeks. Controls received vehicle. For each treatment subgroup (including controls), at least six tumour-bearing mice were used for data analysis.
Immunohistochemical staining
The immunohistochemical staining procedure has been described (Liu et al, 2013) . The primary antibodies against KIAA1524 (ab84547; Abcam, Cambridge, UK) and p-Akt (pAkt1/2/3 Thr308, Santa Cruz, sc-16646-R) were used at 1:100 and 1:200 dilution for a 1-h incubation at room temperature, respectively. The slides were then counterstained with haematoxylin stain solution. Rabbit IgG was used as a control for antibody specificity. To detect apoptosis, tumour tissue samples were immunohistochemically stained by the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) method with S7100 ApopTag â peroxidase in situ Apoptosis Detection Kit (Merck Millipore Corporation, Darmstadt, Germany), according to the manufacturer's instructions. Staining signals were detected using the EnVisionTM system (Dako, Carpinteria, CA, USA).
Reverse transcription-polymerase chain reaction
Total RNA was extracted from cultured cells using TRIzol Reagent (Invitrogen) and reverse transcription-PCR (RT-PCR) was performed according to the manufacturer's instructions (MBI Fermentas, Vilnius, Lithuania). RT-PCR analyses were performed as previously described (Tseng et al, 2012) , using specific primers for human KIAA1524 (forward primer, 5 0 -TGGCAAGATTGACCTGGGATTTGGA-3 0 ; reverse primer, 5 0 -AGGAGTAATCAAACGTGGGTCCTGA-3 0 ; 172 bps), and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was chosen as an internal control (forward primer, 5 0 -CGACCACTTTGTCAAGCTCA-3 0 ; reverse primer, 5 0 -AGGGGTCTACAT GGCAACTG-3 0 ; 228 bps). Real-time quantitative PCR was performed in a LightCycler 480II instrument (Roche Diagnostics, Indianapolis, IN, USA) using a LightCycler 480 SYBR Green I Master kit (Roche Diagnostics). Primers are the same as described above.
Human and leukaemia cell colony-forming unit granulocyte-macrophage assay in Petri dishes CD34 + normal haematopoietic cells and leukaemia cells were treated with 100 nmol/l carfilzomib for 24 h; each sample was then washed and seeded in MethoCult-H4534 (StemCell Technologies, Vancouver, BC, Canada) medium in 35-mm dishes. This medium contains colony-stimulating factor, methylcellulose, fetal bovine serum, bovine serum albumin, 2-mercaptoethanol, glutamine, interleukin-3 (IL3), granulocyte-macrophage colony-stimulating factor and stem cell factor, without erythropoietin, as described by the manufacturer. Each culture sample contained 1 9 10 5 lowdensity CD34 + cells. Cultures were incubated at 37°C in 5%
CO 2 for 14 days and colonies were scored.
The Cancer Genome Atlas data description
Patient tumour subtypes and gene expression data for AML was accessed from The Cancer Genome Atlas (TCGA) public data portal (https://tcga-data.nci.nih.gov/tcga/). Level 3 released gene level expression data RNAseq were downloaded. The data processing and quality control were conducted by Broad Institute's TCGA workgroup (National Cancer Institute and National Human Genome Research Institute, Bethesda, MD, USA). The RNAseq gene expression level 3 data contains Reads per Kilobase per Million mapped reads (RPKM) (Mortazavi et al, 2008) and RNAseq by Expectation-Maximization (RSEM) (Li & Dewey, 2011) . RPKM is a widely used RNAseq normalization method, and is computed as follows: RPKM = 10 9 (C/NL), where C is the number of reads mapped to the gene, N is the total number of reads mapped to all genes, and L is the length of the gene. RPKM values of KIAA1524 gene expression were retrieved and analysed according to clinical factors. For survival analysis from the TCGA dataset of AML cases, RSEM z-scored values using z-score transformation (Cheadle et al, 2003) were retrieved and a cut-off value of 2 was defined for higher versus lower KIAA1524 expression.
Statistical analysis
Data are expressed as mean AE standard deviation (SD) or standard error (SE). Statistical comparisons were based on nonparametric tests and statistical significance was defined at P < 0Á05. Protein levels were quantified by ImageJ software (U.S. National Institutes of Health, Bethesda, MD, USA). For survival analysis, progression-free survival curves of patients were generated by the Kaplan-Meier method and compared by log rank test. All statistical analyses were performed using (Foran, 2010) , showed a higher trend of KIAA1524 mRNA expression ( Fig 1A) . Survival analysis from the TCGA dataset of AML cases demonstrated that higher KIAA1524 transcript expression (defined as RSEM z-scored values ≥2 using z-score transformation (Cheadle et al, 2003) were associated with trends towards worse overall survival ( Fig 1B) and diseasefree survival (Fig 1C) in patients with AML. We then tested the effect of carfilzomib from 10 patients with leukaemia (1 with marrow Burkitt lymphoma) whose characteristics are shown in Table I . As shown in Fig 1D, carfilzomib induced apoptosis (shown as specific cell death) in some primary cells, correlating with its downregulation of KIAA1524.
Carfilzomib exerts an apoptotic effect on leukaemia cells independent of proteasome activity
To investigate the cellular effects of carfilzomib on leukaemia cells, we conducted 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays and flow cytometric analysis on a panel of four human myeloid leukaemia cell lines (HL-60, KG-1, THP-1, and K562). Carfilzomib treatment significantly reduced cell viability in the tested cell lines except K562 cells (Fig 2A) and the reduction in cell viability was due to cell apoptosis (Fig 2B) , indicating that carfilzomib induces anti-proliferation and apoptosis of leukaemia cells. Next, we examined the effects of carfilzomib on colonyforming abilities of leukaemia cells and normal haematopoietic cells using the colony-forming unit granulocyte-macrophage assay. We found that carfilzomib significantly suppressed the colony-forming ability of leukaemia cells as well as CD34 + normal haematopoietic cells (Fig S1) . To further elucidate whether the apoptotic effect of carfilzomib is associated with proteasome inhibition, we examined the proteasome activity of the four leukaemia cell lines after carfilzomib treatment. Carfilzomib inhibited proteasome activities not only in carfilzomib-sensitive but also in resistant K562 cell lines (Fig 2C) , suggesting that the effect of carfilzomib on proteasome inhibition is not associated with its apoptotic effect on leukaemia cells. In agreement with the reduction in proteasome activity, carfilzomib induced accumulation of ubiquitin-conjugated proteins (Fig 2D) . In addition, the accumulation of pro-apoptotic Bax and JNK activation were also observed at 12 h after treatment in both sensitive (HL-60) and resistant (K562) cell lines (Fig 2E) (Li & Dou, 2000; Kuhn et al, 2007) . Together, these results indicate that carfilzomib exerts an apoptotic effect on leukaemia cells in a proteasome-independent manner.
KIAA1524-PP2A-p-Akt axis determines carfilzomibmediated leukaemia cell apoptosis
Previously, the KIAA1524-PP2A-p-Akt pathway was shown to mediate the bortezomib-induced cell apoptosis in solid tumours (Lin et al, 2012) . Here, we examined the effect of carfilzomib on KIAA1524 and its associated molecular events in leukaemias. Carfilzomib induced down-regulation of KIAA1524 and p-Akt in a dose-and time-dependent manner in sensitive cell lines, but not in resistant K562 cells (Fig 3A,  B) . Ectopic overexpression of KIAA1524-protected sensitive cells (HL-60) from carfilzomib-induced cell apoptosis (Fig 4A) , suggesting that KIAA1524 plays a role in carfilzomib-induced apoptosis. Meanwhile, PP2A activity was enhanced by carfilzomib in drug-sensitive HL-60 cells (Fig 4B) . We therefore validated whether PP2A is involved in carfilzomib-induced leukaemia cell apoptosis. Cellular PP2A activity was manipulated by treating cells with OA, a PP2A inhibitor) or forskolin (a PP2A activator). PP2A inhibition protected carfilzomib-sensitive cells from apoptosis while PP2A activation sensitized resistant K562 cells to cell death (Fig 4C-D, upper) . Furthermore, p-Akt levels were inversely correlated with PP2A activity and the percentage of apoptotic cells (Fig 4C-D, lower) . These results indicate that PP2A activity determines the apoptotic effect of carfilzomib on leukaemia cells. In summary, our results demonstrate that carfilzomib induces leukaemia cell apoptosis through the KIAA1524-PP2A-p-Akt signalling pathway.
Carfilzomib inhibits KIAA1524 expression at the transcriptional level
Next, we investigated how carfilzomib regulates KIAA1524 expression. First, we tested whether the effect of carfilzomib on KIAA1524 is at the protein level. As shown in Fig 5A, in the presence of CHX (a protein synthesis inhibitor), carfilzomib did not accelerate the degradation of KIAA1524, suggesting that carfilzomib-mediated downregulation of may not cause by a post-translational effect. We next examined transcription of KIAA1524. RT-PCR results showed that after drug treatment, KIAA1524 mRNA was suppressed in a dose-dependent manner in carfilzomib-sensitive leukaemia cell lines, but not altered in resistant K562 cells (Fig 5B) . Our results suggested that carfilzomib inhibited KIAA1524 expression at the transcriptional level. Next, we investigated the mechanism by which carfilzomib regulates transcription of KIAA1524. We hypothesized that an unknown transcriptional factor mediates the effect of carfilzomib on KIAA1524 transcription. To this end, a serial deletion analysis of the KIAA1524 promoter was performed. HL-60 cells transfected with -110/-1 construct did not respond to carfilzomib (Fig 5C) . This finding suggests that the carfilzomib-responsive KIAA1524 promoter region is between -110 and -150 ( Fig 5C) . Sequence analysis of this region identified a putative ELK1 binding site (Pallai et al, 2012) .
Therefore, we studied the role of ELK1 in mediating the effect of carfilzomib on KIAA1524 in leukaemia cells. ELK1 protein level was downregulated and the association between ELK1 and KIAA1524 promoter was reduced by carfilzomib (Fig 5D,E) . Moreover, ectopic expression of ELK1 restored KIAA1524 expression and protected carfilzomib-sensitive leukaemia cells against apoptosis (Fig 5F) . Taken together, our results suggest that carfilzomib may inhibit KIAA1524 by attenuating expression levels and interfering with the DNAbinding ability of ELK1.
In vivo effect of carfilzomib on HL-60 and K562 xenograft nude mice
To determine whether carfilzomib could augment antitumour activity in vivo, mice were inoculated with carfilzomibsensitive HL-60 cells or resistant K562 cells, followed by (Fig 6A-B, left) , but not in the K562 xenografts (Fig 6A-B, right) . Carfilzomib treatment did not significantly alter the weight of mice (Fig S2) . To correlate the regression of tumour growth with the molecular events found in vitro, the xenografted tumours were subjected to PP2A activity assay, Western blot and immunohistochemistry analysis. Mirroring the mechanism identified in vitro, there was enhanced PP2A activity and low levels of KIAA1524 and p-Akt in the HL-60 tumours treated with carfilzomib (Fig 6C-D, left) , while no significant changes were observed in the K562 tumours (Fig 6C-D, right) . Notably, the downregulation of KIAA1524 and p-Akt were associated with apoptosis in vivo ( Figs 6D and 7A , caspase 3 and TUNEL staining). In summary, these results demonstrate that the drug sensitivity and the anti-tumour activity of carfilzomib in xenograft mouse models correlated well with the effect of carfilzomib on KIAA1524/PP2A/p-Akt signalling (Fig 7B) .
Discussion
In this study, we demonstrate that the KIAA1524/PP2A/pAkt signalling pathway plays a vital role in carfilzomib- mediated leukaemia cell apoptosis. The sensitivity of leukaemia cells/tumours to carfilzomib is significantly correlated with KIAA1524 expression, PP2A activity and p-Akt levels. Of importance, our data reveals a novel drug mechanism of carfilzomib in leukaemia and suggests that KIAA1524 could be a candidate for functional re-activation of PP2A for antileukaemia therapy. Our finding has several important implications.
We identified a new drug target mechanism of carfilzomib. Our results showed that the anti-leukaemia activity of carfilzomib is not necessarily dependent on its proteasome inhibition (Fig 2C-E) . Instead, the sensitivity of leukaemia cells was significantly correlated with KIAA1524 levels (Figs 3-4) .The clinical relevance of KIAA1524 in leukaemia has been reported recently (Lucas et al, 2011; Wang et al, 2011; Barragan et al, 2015) . Carfilzomib, alone or in combination with chemotherapy is currently undergoing several early phase trials for the treatment of relapsed or refractory leukaemia (NCT clinical trials: NCT01137747, NCT02303821, NCT02512926). We believe the impact of KIAA1524 After treatment with 100 nmol/l of carfilzomib for 24 h, HL60 cells were lysed and total cell extract, cytoplasmic and nuclear fractions were prepared. Equal amounts of proteins were loaded into each well and Western blotted for KIAA1524 and ELK1. Tubulin was used as markers for cytosolic and lamin B for nuclear fractions. (E) ELK1 associated with KIAA1524 promoter after carfilzomib treatment. HL60 cells were exposed to carfilzomib at 100 nmol/l for 24 h then fixed for chromatin immunoprecipitation (ChIP) assay. ChIP samples were immunoprecipitated with ELK1, IgG (negative control), and RNA pol II (positive control) antibodies. Then, KIAA1524 promoter fragments were amplified by PCR. The result of ChIP assay was determined by gel-electrophoresis. (F) Ectopic expression of ELK1 restores KIAA1524 expression and attenuates apoptotic effect of carfilzomib. HL60 cells were transfected with pCMV6-ELK1-GFP for 48 h and exposed to carfilzomib (100 nmol/l) for 12 h. Means of at least three independent experiments performed in triplicate are shown. *P < 0Á05. Data are shown as mean AE SD. targeting by carfilzomib and the subsequent molecular events in leukaemia will be helpful to improve carfilzomib-related clinical studies. Interestingly, carfilzomib is a second-generation proteasome inhibitor that is structurally and mechanistically different from bortezomib; however, both proteasome inhibitors share similar mechanisms of action in cancer cells. These findings again highlight the importance of the KIAA1524-PP2A-p-Akt pathway in cancer survival signalling and the pharmacological potential of KIAA1524 inhibition for anti-cancer therapy.
The major Ser/Thr-specific phosphatases have been classified into four main types, Protein phosphatase types 1, 2A, 2B (calcineurin), and 2C (PP1, PP2A, PP2B, and PP2C, respectively) (Oliver & Shenolikar, 1998) . These enzymes differ in their substrate specificity, divalent cation requirement, and sensitivity to inhibitors (Oliver & Shenolikar, 1998) . Previous studies have shown that OA inhibits PP2A at low nanomolar concentrations, whereas it inhibits PP1 and PP2B at much higher concentration levels (Cohen et al, 1989) . In contrast, PP2C activity is unaffected by OA (Bialojan & Takai, 1988; Ishihara et al, 1989) . Given that OA has been shown to be a relatively selective inhibitor for PP2A and PP1 (Chatfield & Eastman, 2004) , and our data showed that OA reduced carfilzomib-induced effects on p-Akt (Fig 4C) , it is speculated that PP1 may also be involved in the carfilzomibrelated pathway. To address the issue, we performed a PP1A (the most common catalytic subunit of PP1) activity assay on carfilzomib-treated leukaemia cells. However, carfilzomib did not significant affect the Ser/Thrphosphatase activity of PP1A, suggesting a minor role of PP1 in the carfilzomibrelated pathway (Fig S3) . Besides, under our experimental conditions, the OA concentration chosen (25 nmol/l) effectively inhibited the activity of PP2A by c. 50% (Fig 4) , but was insufficient to reduce the activity of PP1 (Fig S4) , confirming that the effect on p-Akt (Fig 4C) was mainly caused by PP2A inhibition. On the other hand, forskolin treatment reduces the phosphorylation of the C-terminal tail PP2A C subunit Y307, thereby activating PP2A (Feschenko et al, 2002; Cristobal et al, 2011 Cristobal et al, , 2014 . As shown in Fig 4, 1,9 dideoxy-forskolin (a forskolin derivative that does not alter the cAMP level) effectively induced the activity of PP2A, but had no obvious effect on PP1 activity (Fig S4) in HL-60 cells. However, PP1 is known for regulating diverse, essential cellular processes through interaction with at least 200 known and about 650 predicted interacting proteins (Bollen et al, 2010; Peti et al, 2013) , whether carfilzomib also affect these PP1-interacting proteins need further investigation.
The fact that K562 leukaemia cells are more resistant to carfilzomib than others may be due to the persistent expression of KIAA1524 ( Figs 3A-B and S5 ). To dissect the resistance mechanism in detail, we observed the effect of carfilzomib on KIAA1524 expression in short-term exposure. Surprisingly, we found that KIAA1524 expression was transiently increased after treatment for 2 h (Fig S5) . Treating cells with carfilzomib-conditioned medium induced upregulation of ELK1/KIAA1524 (Fig S6) , suggesting the presence of an autocrine/paracrine mode of action. Recent reports have shown that in lung adenocarcinoma, IL10, which is secreted from malignant and immune cells, promoted tumour progression through upregulation of KIAA1524 (Sung et al, 2013) . Carfilzomib resistance of K562 might be attributed to IL10 production and its receptor (IL10R) expression. IL10 has been considered as a growth factor for myeloma cells and differentially expressed in human myeloma cell lines (Otsuki et al, 2000) . Further investigation is required to examine the role of IL10/IL10R in carfilzomib resistance in leukaemia. In addition, K562 cells were originated from the pleural effusion of a 53-year-old female with CML in terminal blast crises (Lozzio & Lozzio, 1975) , that harbored multiple chromosome abnormalities including Philadelphia chromosome (leading to activated bcr-abl kinase activity) and may have cytogenetic evolution during passages (Gribble et al, 2000) , suggesting a propensity to drug-resistance. Further, it has been reported that PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein (Neviani et al, 2005) . In contrast, Lucas et al (2011) showed that high KIAA1524 expression is associated with CML blast crisis and that a KIAA1524/MYC/E2F1 positive feedback loop might explain imatinib resistance (Lucas et al, 2015) . They also demonstrated that the second generation BCR-ABL kinase inhibitors, dasatinib and ninlotinib, could suppress KIAA1524, leading to decreased MYC and E2F1, reactivation of PP2A, and a decrease in BCR-ABL tyrosine kinase activity (Lucas et al, 2015) . Collectively, future investigation is necessary and it will be interesting to see whether the aberrant bcr-abl oncogenic kinase activity, as well as the potential interplay or feedforward/feedback loops between the PP2A and its intrinsic inhibitors SET and KIAA1524 confer carfilzomib resistance in K562 cells.
Notably, carfilzomib has an effect on KIAA1524 expression at the transcriptional level (Fig 5) . KIAA1524 promoter analysis revealed the involvement of ELK1 in carfilzomibmediated KIAA1524 downregulation even though it remains unclear how ELK1 is regulated by carfilzomib. An earlier study reported two functional elements (a short region in the EST domain and a cryptic degron) in ELK1 determine its stability and nuclear accumulation (Evans et al, 2011) . It is possible that carfilzomib targets ELK1 through the two motifs and contributes to ELK1 degradation. On the other hand, KIAA1524 transcription is also regulated by microRNAs (Jung et al, 2013 (Jung et al, , 2014 Wei et al, 2014) , suggesting that carfilzomib might suppress KIAA1524 by interplay with microRNAs. Moreover, Lucas et al (2015) recently reported a role of E2F1 in CML patients with high KIAA1524 levels (Lucas et al, 2015) . The authors depicted a mechanism in which high level KIAA1524 inhibits PP2Ac, stabilizing E2F1, and activating KIAA1524 transcription to form a positive feedback regulation. We speculate that carfilzomib may have effect on E2F1-mediated KIAA1524 transcription. Recently, afatinib and lapatinib were shown to induce cell apoptosis through the ELK1/ KIAA1524/PP2A/Akt pathway in non-small cell lung cancer (Chao et al, 2015) and triple negative breast cancer cells (Liu et al, 2016) , suggesting that ELK1/KIAA1524/PP2A/Akt signalling is a potential target for cancer therapy.
In summary, this study has highlighted a promising therapeutic pathway for leukaemia treatment -inhibition of KIAA1524 for PP2A re-activation. We showed that modulation of ELK1/KIAA1524/PP2A/p-Akt signalling by carfilzomib induces leukaemia cell apoptosis in vitro and inhibits tumour growth in vivo. Our data disclosed a novel drug mechanism of carfilzomib in leukaemia cells and suggests the therapeutic potential of manipulation of KIAA1524 in leukaemia treatment.
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Fig S2. Body weight of xenograft mice bearing HL-60 or K562 tumors treated with vehicle or carfilzomib. Fig S3. Carfilzomib did not significant affect the activity of PP1. Fig S4. Okadaic acid and forskolin have no obvious effect on PP1 activity in HL-60 cells. Fig S5. HL-60 and K562 cells were exposed to carfilzomib 100 nmol/l for the indicated length of time. Fig S6. The effect of conditioned medium from carfilzomib-treated cells on HL-60.
